On the heels of a strong start for Medtronic’s fiscal year 2025, CEO Geoff Martha credited one of the company’s key product lines for spine growth in an Aug. 20 earnings call.

Medtronic saw modest revenue growth in the first quarter of fiscal year 2025 with $7.9 billion in sales and net income of $1 billion. Mr. Martha said he expects the company’s surgical business to reach “normalized” growth in the second half of the fiscal year.

“Our spine business continues to just really outperform the market with 7% global and 9% U.S. core spine growth,” he said, as transcribed by Seeking Alpha. “This sustained share capture is being driven by our AiBLE ecosystem. AiBLE’s differentiated features and the sheer scale around the world is — it’s a winning formula for our spine business.”

The AiBLE surgical suite includes Mazor robotics, Stealthstation S8 navigation, O-arm imaging and UNiD adaptive spine intelligence technology according to Medtronic’s website.

“It’s good for patients and surgeons, and it’s changing the competitive dynamics in spine.”